FIELD: biotechnology.
SUBSTANCE: antibody or its antigen-binding portion that binds to OX40 (CD134) is proposed. Also a bispecific antibody that binds to OX40 and a programmed cell death protein 1 (PD-L1) ligand is provided. Nucleic acids encoding the said antibodies are also disclosed. In addition, the use of these antibodies, including as part of a pharmaceutical composition, for the treatment of cancer selected from prostate cancer, lung cancer, non-small cell lung cancer, melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma and ovarian cancer is proposed.
EFFECT: invention provides improved agonistic activity of antibodies in T-cell activation.
14 cl, 36 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| BISPECIFIC ANTIBODIES AND METHODS FOR THEIR PRODUCTION AND USE | 2018 |
|
RU2787783C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
